# EDGAR Filing Document

**Accession Number:** 0001872812
**File Stem:** 0001493152-25-023773
**Filing Date:** 2025-11
**Character Count:** 3556
**Document Hash:** 670427f20f5f99f02eab747f01beff7f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-023773.hdr.sgml**: 20251117

**ACCESSION NUMBER**: 0001493152-25-023773

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251117

**FILED AS OF DATE**: 20251117

**DATE AS OF CHANGE**: 20251117

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TC BioPharm (Holdings) plc
- **CENTRAL INDEX KEY:** 0001872812
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41231
- **FILM NUMBER:** 251489441

**BUSINESS ADDRESS:**
- **STREET 1:** MAXIM 1
- **STREET 2:** 2 PARKLANDS WAY
- **CITY:** HOLYTOWN
- **STATE:** X0
- **ZIP:** ML1 4WR
- **BUSINESS PHONE:** 01414337557

**MAIL ADDRESS:**
- **STREET 1:** MAXIM 1
- **STREET 2:** 2 PARKLANDS WAY
- **CITY:** HOLYTOWN
- **STATE:** X0
- **ZIP:** ML1 4WR

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TC BioPharm (Holdings) Ltd
- **DATE OF NAME CHANGE:** 20210721

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TC BioPharm Ltd
- **DATE OF NAME CHANGE:** 20210714

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of**

**the Securities Exchange Act of 1934**

**For the month of November 2025**

**Commission File Number 001-41231**

**TC BIOPHARM (HOLDINGS) PLC**

(Translation of registrant's name into English)

**Maxim 1, 2 Parklands Way**

**Holytown, Motherwell, ML1 4WR**

**Scotland, United Kingdom**

**+44 (0) 1698 209100**

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____ ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____ ☐

<u>TC BioPharm (Holdings) plc</u>

On November 10, 2025, the directors of TC BioPharm (Holdings) plc ("the Company") resolved to appoint Ben Cairns and Michael Magnay of Alvarez and Marsal Europe LLP ("A&M") as interim liquidators of TC BioPharm (Holdings) plc. Addleshaw Goddard LLP have been authorised and directed on behalf of the Directors of the Company to file with the Court the relevant documentation as may be required, and to take all steps necessary in respect of the Directors' appointment of the proposed liquidators to the Company.

The Company intends to file a Form 15 with the Securities and Exchange Commission ("SEC") in due course to deregister its American Depositary Shares ("ADSs") under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Company's obligation to file periodic reports under the Exchange Act will be suspended immediately upon the filing of the Form 15.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **TC BIOPHARM (HOLDINGS) PLC** | **TC BIOPHARM (HOLDINGS) PLC** |
| Date: November 17, 2025 | By: | */s/ Martin Thorp* |
|  |  | Martin Thorp |
|  |  | Chief Financial Officer |

---